While the wave of small molecule drug therapies going off patent has peaked, there are still a number that will be losing patent protection over the coming years. The need for rapid development of new generic equivalents is as critical as it has ever been. One of those drugs reaching the end of its patent …
Impact of Biomarkers on Current Parkinson’s Disease Treatment Research
About a century ago, Otto Loewi discovered in his laboratories in Graz, Austria, that nerve impulses are transmitted by chemical messengers like acetylcholine. Since then, the field of neuroscience has advanced significantly and the scientific interest in this research field rapidly grew. It became obvious that disturbed neurotransmission is a common characteristic of many neurodegenerative …
Inflammatory Disease Models and Biomarkers
Trained and supervised by internationally recognized experts, we have acquired skills in a variety of inflammatory disease models at QPS. Such models can be applied to study immune responses, biomarkers, and the pathophysiology following specific triggers and for proof of concept studies with (targeted) interventions. Disease models also offer the advantage of (non-invasive) biomarker samplings, …
Accelerating Pharmaceutical Breakthroughs for CNS Disorders
Although we’ve made great progress in our understanding of the central nervous system (CNS) and the disorders that affect it, CNS drug development continues to pose many challenges. The high failure rate may seem discouraging, but it’s important to remember that failure is an inevitable component of innovation. With Alzheimer’s and other forms of dementia …
DDI Studies: The Final Frontier?
QPS recognizes the importance of well-conducted clinical trials on drug-drug interactions. Historically, the CYP450 interactions provided valuable information for the safe use of drugs, being an inhibitor, inducer or substrate of one or more of the CYP isoenzymes. In addition, studies on phenotyping-genotyping helped to understand the behavior of a number of drugs in genetically …
Challenging the Inhaled Allergen Challenge
Presently, the QPS Respiratory Team is making progress on a large data-intensive, 2-centre allergen challenge study in eosinophilic allergic asthma testing an innovative new drug in close collaboration with our partnering University Centres: Amsterdam (AMC) and Groningen (UMCG). This study is a good example of QPS’ scientific expertise and partnership with academic networks-of-excellence. This enables …
Client Feedback — Our Gold Standard
At QPS, we love making customers happy. Here’s what two of them had to say about our work in DMPK protein binding studies: First of all, my compliments and thanks for the work that Wenbin and the other members of the QPS team did on the XYZ protein binding study. Lots of samples, lots of …
QPS Assay Finder Database Grows 47 New Assays!
For all you assay aficionados out there, we thought you’d be juiced to know — we just added a whopping 47 new assays to the QPS Assay Finder Database: Agomelatine; Albendazole + metabolite; Amphetamine; Apixaban; Apremilast; Atazanavir; Atorvastatin + metabolites; Bosutinib; Bupropion + metabolites; Caffeine + metabolites; Carbamazepine + metabolite; Cetirizine; Chlorzoxazone; Colchicine; Dexamethasone; Dolutegravir; …
SCIEX and QPS Join Forces to Bring You a New Bioanalysis Solution for Biologics
Over the past 10 years, large molecule therapies have increased from 10% to nearly 50% of the typical pharma and biopharmaceutical pipeline. This transition has created new challenges in the industry. To address these challenges and boost productivity, QPS has teamed up with SCIEX, a global leader in life science analytical technologies, to advance a …
QPS Now Has Exclusive Distribution Rights for Samsara’s Specialized Human Liver Cells
QPS and Samsara Sciences have solidified a cell supply partnership for the production, characterization and distribution of primary human liver cells including hepatocytes and hepatic stellate cells for research. QPS now has exclusive rights to distribute Samsara’s primary human hepatocytes. At the same time, the two companies will also cooperate to provide specialized non-parenchymal hepatocytes …
